Eiger BioPharmaceuticals (EIGR) Tops Q1 EPS by 87c

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q1 EPS of $0.85, $0.87 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $13 million.

"The Phase 3 D-LIVR study is now 75% enrolled, and by year-end we expect to complete enrollment of this landmark global study advancing Lonafarnib, the only oral agent in development for HDV, setting the stage for Week 48 end of treatment data in 2022," said David Cory, President and CEO of Eiger. "In parallel, we will initiate the Phase 3 LIMT-2 study in 2021 to advance Lambda, a well-tolerated interferon, also toward registration for HDV. Most recently, with a goal of developing a convenient, outpatient treatment for COVID-19, we announced that a Lambda arm will be included in the ongoing, multi-center, Phase 3 TOGETHER platform study in Brazil."

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Reading (RDI) Tops Q2 EPS by 4c